Circulating tumor-derived PTHrP, MIP-1α, IL-1, IL-6, and TNF-α have been identified in the serum of ATL patients and are factors underlying the clinical tumor-associated bone manifestations [4,6,21,40]. This evidence concerns the gene IL6 and neoplasm.